CytoDyn Inc. (CYDY)

CytoDyn Income Statement

Financials in millions USD. Fiscal year is June - May.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 31, 2024	May 31, 2023	May 31, 2022	May 31, 2021	May 31, 2020
Revenue	-	-	0.27	-	-
Cost of Revenue	-	20.63	73.54	5.03	-
Gross Profit	-	-20.63	-73.28	-5.03	-
Selling, General & Admin	10.79	17.14	44.3	34.32	19.97
Research & Development	7.24	2.63	27.04	53.4	52.64
Operating Expenses	18.06	19.94	72.13	89.52	74.65
Operating Income	-18.06	-40.58	-145.4	-94.55	-74.65
Interest Expense	-8.67	-15.51	-24.18	-22.11	-33.25
Other Non Operating Income (Expenses)	-3.06	-18.43	-	-	-9.54
EBT Excluding Unusual Items	-29.79	-74.51	-169.59	-116.66	-117.44
Asset Writedown	-	-	-	-10.05	-
Legal Settlements	-	-	-3.85	-10.63	-22.5
Other Unusual Items	-20.05	-5.31	-37.38	-39.13	-
Pretax Income	-49.84	-79.82	-210.82	-176.47	-139.94
Net Income	-49.84	-79.82	-210.82	-176.47	-139.94
Preferred Dividends & Other Adjustments	1.48	6.91	1.63	1.69	0.71
Net Income to Common	-51.32	-86.74	-212.45	-178.15	-140.64
Shares Outstanding (Basic)	970	837	677	588	421
Shares Outstanding (Diluted)	970	837	677	588	421
Shares Change (YoY)	15.90%	23.58%	15.20%	39.54%	54.78%
EPS (Basic)	-0.05	-0.10	-0.31	-0.30	-0.33
EPS (Diluted)	-0.05	-0.10	-0.31	-0.30	-0.33
Free Cash Flow	-10.98	-25.11	-77.72	-117.7	-68.85
Free Cash Flow Per Share	-0.01	-0.03	-0.12	-0.20	-0.16
Operating Margin	-	-	-54663.16%	-	-
Profit Margin	-	-	-79867.67%	-	-
Free Cash Flow Margin	-	-	-29219.17%	-	-
EBITDA	-18.03	-40.4	-144.62	-92.75	-72.61
D&A For EBITDA	0.03	0.18	0.78	1.8	2.03
EBIT	-18.06	-40.58	-145.4	-94.55	-74.65

Updated Jan 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.